The MedTech Funding Mandate (MTFM) policy launched on 1 April 2021.

In 2021/22 the policy will support devices, diagnostics or digital products that:

  • are effective: demonstrated through positive NICE guidance;
  • deliver material savings to the NHS: the benefits of the innovation are over £1 million over five years for the population of England;
  • are cost-saving in-year: NICE modelling demonstrates a net saving in the first 12 months of implementing the technology;
  • are affordable to the NHS: the budget impact should not exceed £20 million, in any of the first three years.

To minimise burden on the NHS at this time, it was agreed that for the first year of the policy only, technologies must have also been previously supported by the Innovation Technology Payment.

The technologies that will be supported by the policy in 2021/22 are:

1.     Placental growth factor based testing (PlGF) – a blood test to rule out pre-eclampsia in pregnant women. Find out more about PlGF in this short film with Guy Checketts, Interim Director of Strategic and Industry Partnerships at Oxford AHSN and National AHSN Lead for PlGF-based testing.

2.     SecurAcath – for securing percutaneous catheters. Find out more about SecurAcath in this short film with Jennifer Miller, National Clinical Specialist at Aquilant Healthcare 21, the UK distributor of SecurAcath.

3.     HeartFlow – creates a 3D model of a patient’s coronary arteries and assesses the extent and location of blockages. Find out more about HeartFlow in this short film with Gina McDonald-Main, Vice President Government Affairs at HeartFlow.

4.     gammaCore – a handheld device which alleviates the symptoms of severe cluster headaches. Find out more about gammaCore in this short film with Iain Strickland, Vice President Global Sales and Strategy at electroCore.

The guidance for 2021/22 is published here.

2022 / 2023 MedTech Funding Products

Benign Prostatic Hyperplasia 

1.  UroLift: The UroLift system lifts and holds the enlarged prostate tissue away from the urethra, relieving the compression of this organ.

2.  GreenLight XPS: Vaporises prostatic tissue with a laser, it vaporises the enlarged prostate tissue, leaving a clear urethral channel.

3.  Rezum: Delivers targeted, controlled doses of stored thermal energy in water vapour directly to the region of the prostate gland with the obstructive tissue causing lower urinary tract
symptoms (LUTS).

4.  Plasma: Is a bipolar electrosurgery system for transurethral resection and haemostasis of the prostate. It uses electrodes to cut out (resect) prostate tissue and stop any local bleeding afterwards (haemostasis), which avoids the risk of transurethral resection syndrome and reduces the need for blood transfusion.

Improving the Patient Experience during procedures

1.   XprESS multi-sinus dilation system: Dilation of the XprESS balloon remodels the bony sinus outflow tract by displacing adjacent bone and paranasal sinus structures. This reduces the tissue lost compared to traditional functional endoscopic sinus surgery (FESS) procedures.

2.  Thopaz+ portable digital system: Digital chest drain system that provides regulated negative pressure close to the patient’s chest and continuously monitors and records air leak and fluid drainage.  Sensors in the system turn the pump on and off to ensure the pressure level set by the healthcare professional is precisely maintained.

3.  Spectra Optia: Is an apheresis and cell collection platform for the treatment of sickle cell disease. It separates and removes sickle red blood cells from the patient’s blood using continuous flow and centrifugation.

Find out more information here.

About the Accelerated Access Collaborative

The NHS Accelerated Access Collaborative (AAC) team will regularly review NICE guidance on medical technologies and diagnostics to identify medical devices, diagnostics and digital products which have been recommended by NICE and are likely to meet the MedTech Funding Mandate criteria in the following year, and highlight these to providers and commissioners.

Together with technology suppliers, the AAC will work with patients, delivery partners, and the AHSN Network, to support NHS organisations to implement these innovations. This helps enable the understanding of local and regional issues and to share learning from NHS organisations that have already implemented the innovations. This will help identify barriers to their uptake, such as duplicative procurement processes.

The AAC expects hospitals and commissioning organisations to comply with the policy guidance where appropriate. The AHSN delivery partners will work closely with commissioners, providers, clinicians, patient groups and others, to understand the impact of the policy and support its development.